Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
29,277
Total Claims
$1.6M
Drug Cost
860
Beneficiaries
$1,886
Cost/Patient
Risk Score Breakdown 17/100
Score components are additive. Read full methodology
Peer Comparison vs. 7,389 General Practice providers
-98%
Opioid rate vs peers
0.0% vs 2.5% avg
+67%
Cost per patient vs peers
$1,886 vs $1,128 avg
+21%
Brand preference vs peers
10.2% vs 8.4% avg
Brand vs Generic
Brand: 2,954 claims · $1.3M
Generic: 26,035 claims · $345K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dapagliflozin Propanediol | 292 | $186K |
| Apixaban | 249 | $157K |
| Empagliflozin | 170 | $126K |
| Insulin Glargine,hum.Rec.Anlog | 146 | $76K |
| Empagliflozin/Metformin Hcl | 120 | $71K |
| Empagliflozin/Metformin Hcl | 72 | $52K |
| Linagliptin | 67 | $49K |
| Empaglifloz/Linaglip/Metformin | 78 | $45K |
| Empagliflozin/Linagliptin | 57 | $35K |
| Sodium Zirconium Cyclosilicate | 36 | $28K |
| Sitagliptin Phos/Metformin Hcl | 46 | $28K |
| Sitagliptin Phosphate | 40 | $26K |
| Insulin Lispro | 72 | $24K |
| Insulin Lispro Protamin/Lispro | 37 | $23K |
| Rivaroxaban | 32 | $21K |
Prescribing Profile
Patient Profile
78
Avg Age
61%
Female
2.32
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data